MAHA🇺🇸
President Trump has signed a memorandum directing @SecKennedy to ensure transparency and accuracy in direct-to-consumer prescription drug advertising and @DrMakaryFDA to enforce the prescription drug advertising provisions of the Federal Food, Drug, and Cosmetic Act. pic.twitter.com/SxyIre2fBB
— The White House (@WhiteHouse) September 9, 2025
Let’s break down these new shackles, because Trump’s not messing around – the memo directs the FDA to enforce existing rules with teeth, sending over 100 warning letters to violators starting September 9, 2025, and threatening shutdowns for non-compliance. Ads can no longer bury the bad news; they must spell out every serious side effect, from blood clots and heart attacks to suicidal thoughts and organ failure, right there in the spot – no more speed-reading disclaimers or redirecting to a website for the dirty details. Contraindications? Front and center – like warnings for pregnant women, folks with liver issues, or drug interactions that could kill. Common precautions too – think “don’t drive” or “avoid alcohol” – all in clear, conspicuous language that doesn’t get drowned out by happy music and smiling actors. It’s “fair balance” on steroids, ensuring the risks aren’t whispered while benefits are shouted, and it’s already forcing longer ads or outright pulls to avoid the hammer.
The effects? Buckle up, because this is where the pharma empire strikes out. First off, ad volumes will crater – with full spews required, those snappy 30-second spots turn into info dumps that bore viewers and tank engagement, potentially slashing the $10 billion DTC spend that exploded after the 1997 FDA loosen-up. Drugmakers will rethink the ROI, pulling back from TV and social media blitzes that drove unnecessary prescriptions – research shows these ads spike demand by 20-30%, leading to overdiagnosis and folks begging docs for pills they don’t need.
Hospitals and consumers win big: Fewer hyped-up demands mean less strain on the system, cutting the $500 billion annual tab for overtreatment. Pharma profits? Hammered – stocks dipped 5-8% for big players like Pfizer and Merck in the two days post-memo, as investors brace for a revenue hit from reduced sales. And the doctor-patient bond? Strengthened – no more distorted chats where ads create false hopes, just honest talks based on facts, not flash.
But wait, the ripple effects go deeper – this crackdown exposes the grift that’s hooked the nation on pricey drugs, with side effect underplays leading to lawsuits and health crises that cost billions yearly. Trump’s move flips the script, empowering folks to make informed choices and curbing the overprescription epidemic that’s fueled opioid horrors and antibiotic resistance. Polls back the tough love: An August 2025 survey showed 62% of Americans want stricter ad rules, with 68% saying pharma ads mislead on risks and 55% blaming them for higher healthcare costs. Independents? 59% approve the changes, tired of the slick sales pitches that pad corporate pockets while families foot the bill.
This is America First in action – Trump’s not banning ads; he’s making ’em honest, stripping the deception that lets Big Pharma play God with your health. The left’s squealing about “free speech,” but it’s code for protecting their donor buddies. Wake up, or keep swallowing the pill of pharma propaganda. Trump’s prescription? Transparency, baby – and it’s just what the doctor ordered.
Help American Liberty PAC in our mission to elect conservatives and save our nation. Support – American Liberty PAC